New study tracks safety of daily MS pill in taiwan patients
NCT ID NCT04480853
Summary
This study aims to monitor the safety of fingolimod (Gilenya), a daily oral medication, in Taiwanese adults newly starting treatment for relapsing-remitting multiple sclerosis. Thirty-four participants will take the medication for one year while researchers track side effects and health changes. The study focuses on identifying potential heart, liver, and eye-related side effects that might occur with this treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGKaohsiung City, 83301, Taiwan
-
Novartis Investigative Site
RECRUITINGTaichung, 407219, Taiwan
-
Novartis Investigative Site
WITHDRAWNTainan, 704302, Taiwan
-
Novartis Investigative Site
RECRUITINGTaipei, 10002, Taiwan
-
Novartis Investigative Site
WITHDRAWNTaipei, 11220, Taiwan
-
Novartis Investigative Site
WITHDRAWNTaoyuan District, 33305, Taiwan
Conditions
Explore the condition pages connected to this study.